Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bartolome Celli

Pulmonary Disease Boston, MA Medical Doctor

NPI 1699762773 CMS profile 76540

75 Francis St, Boston, MA 02115

Open in the dashboard

General payments

$536,200

241 records reported · program years 2019–2025

Research payments

$19,510

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bartolome Celli of Boston, MA is reported in the CMS Open Payments database as having received $536,200 across 241 general payments and $19,510 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78,888 30
2025 Research $3,938 2
2024 General $53,441 24
2024 Research $8,100 6
2023 General $34,654 21
2022 General $67,097 24
2022 Research $500 1
2021 General $76,595 33
2020 General $87,294 50
2019 General $138,231 59
2019 Research $6,972 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bartolome Celli
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Bartolome Celli were reported at $78,888. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Bartolome Celli Pulmonary Disease median Middle half National median
2019 $138,231 $377 $109–$1,340 $163
2020 $87,294 $230 $56–$907 $114
2021 $76,595 $269 $68–$1,072 $132
2022 $67,097 $390 $100–$1,457 $149
2023 $34,654 $419 $114–$1,659 $160
2024 $53,441 $476 $123–$1,818 $164
2025 $78,888 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $160,308 74 payments
  2. GlaxoSmithKline, LLC. $151,455 85 payments
  3. Sanofi US Services Inc. $52,299 14 payments
  4. Chiesi USA, Inc. $51,167 10 payments
  5. Genzyme Corporation $25,032 4 payments
  6. AstraZeneca UK Limited $24,713 11 payments
  7. AstraZeneca AB $17,776 9 payments
  8. F. Hoffmann-La Roche AG $12,634 12 payments
  9. Sanofi-Aventis U.S. LLC $12,048 4 payments
  10. Verona Pharma, Inc. $6,512 2 payments
  11. Other $22,257 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $447,425 137 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $77,720 36 payments
  3. Travel and Lodging $8,775 32 payments
  4. Food and Beverage $2,249 35 payments
  5. Education $32 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA $72,919 13 payments
  2. TRELEGY ELLIPTA $58,656 43 payments
  3. DUPIXENT $39,561 12 payments
  4. BREZTRI $28,083 17 payments
  5. NO PRODUCT DISCUSSED $19,859 2 payments
  6. BREZTRI AEROSPHERE $19,222 12 payments
  7. Ohtuvayre $6,512 2 payments
  8. TEZSPIRE $4,727 3 payments
  9. SPIRIVA $3,438 1 payment
  10. AEROGEN SOLO; AEROGEN ULTRA $2,706 1 payment
  11. Other $16,357 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $11,288 6 payments
  2. Chiesi USA, Inc. $6,972 2 payments
  3. Genzyme Corporation $1,250 3 payments

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record